<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Pro | wechat-feeds</title><link>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</link><description>聚焦生物医药前沿，洞察研发投资风向</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 07 Jun 2021 22:25:58 +0800</pubDate><image><url>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Pro | wechat-feeds</title><link>http://MzU1MTk1NTUwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【聚焦ASCO】B7-H3 ADC临床数据出炉：抗肿瘤活性初显</title><link>https://mp.weixin.qq.com/s/vNP-TJ4IEzzkJQvV7FHKjA</link><description></description><content:encoded><![CDATA[【聚焦ASCO】B7-H3 ADC临床数据出炉：抗肿瘤活性初显]]></content:encoded><pubDate>Mon, 07 Jun 2021 21:04:26 +0800</pubDate></item><item><title>聚焦ASCO 2021：肝癌研究摘要选读</title><link>https://mp.weixin.qq.com/s/2gb0BfCha4dK4xYiQFvHcg</link><description></description><content:encoded><![CDATA[聚焦ASCO 2021：肝癌研究摘要选读]]></content:encoded><pubDate>Sun, 06 Jun 2021 20:59:11 +0800</pubDate></item><item><title>ASCO 2021：新机会TOP10</title><link>https://mp.weixin.qq.com/s/qix8DPSlas7sg7q5A_PurA</link><description></description><content:encoded><![CDATA[ASCO 2021：新机会TOP10]]></content:encoded><pubDate>Sat, 05 Jun 2021 20:59:37 +0800</pubDate></item><item><title>实体瘤CAR-T试验2例患者死亡，细胞疗法教父Carl June公司停止试验</title><link>https://mp.weixin.qq.com/s/i7aXtxWheJFck-TqZ7ujtw</link><description></description><content:encoded><![CDATA[实体瘤CAR-T试验2例患者死亡，细胞疗法教父Carl June公司停止试验]]></content:encoded><pubDate>Fri, 04 Jun 2021 20:58:23 +0800</pubDate></item><item><title>抗衰老新靶点SIRT6：使小鼠预期寿命延长30%，背后机制浮出水面 | Nature子刊</title><link>https://mp.weixin.qq.com/s/H0TXyXUGKQnO8Lex6POufw</link><description></description><content:encoded><![CDATA[抗衰老新靶点SIRT6：使小鼠预期寿命延长30%，背后机制浮出水面 | Nature子刊]]></content:encoded><pubDate>Thu, 03 Jun 2021 21:01:22 +0800</pubDate></item><item><title>吴一龙：什么时候药企CMO敢与PI争吵，那就离创新不远了</title><link>https://mp.weixin.qq.com/s/6k9XB1aZb-zKVW9ZDQFc6Q</link><description></description><content:encoded><![CDATA[吴一龙：什么时候药企CMO敢与PI争吵，那就离创新不远了]]></content:encoded><pubDate>Wed, 02 Jun 2021 21:00:24 +0800</pubDate></item><item><title>白血病潜在first-in-class新药——BAP1抑制剂 | Nature子刊最新成果</title><link>https://mp.weixin.qq.com/s/WhE3cFLr73_o5wJ0OZXKOg</link><description></description><content:encoded><![CDATA[白血病潜在first-in-class新药——BAP1抑制剂 | Nature子刊最新成果]]></content:encoded><pubDate>Tue, 01 Jun 2021 20:58:22 +0800</pubDate></item><item><title>阿尔茨海默症疗法新进展！靶向PAC1R：精确清除有毒tau蛋白，改善小鼠认知能力 | Science子刊</title><link>https://mp.weixin.qq.com/s/1PC6stMvW-9ay1S_RYe64w</link><description></description><content:encoded><![CDATA[阿尔茨海默症疗法新进展！靶向PAC1R：精确清除有毒tau蛋白，改善小鼠认知能力 | Science子刊]]></content:encoded><pubDate>Mon, 31 May 2021 21:00:11 +0800</pubDate></item><item><title>Science子刊报道前列腺癌新疗法：恩扎卢胺“搭档”H6PD抑制剂，显著改善小鼠生存</title><link>https://mp.weixin.qq.com/s/iXw9Bb-ZpDAQmKSnTlOX_A</link><description></description><content:encoded><![CDATA[Science子刊报道前列腺癌新疗法：恩扎卢胺“搭档”H6PD抑制剂，显著改善小鼠生存]]></content:encoded><pubDate>Sun, 30 May 2021 21:00:05 +0800</pubDate></item><item><title>主攻实体瘤细胞疗法！这家“年轻却资深”的公司IPO拟募资1.5亿美元，重点产品靶向ROR-1</title><link>https://mp.weixin.qq.com/s/rwuAK0klHmua9Rltbl7UZw</link><description></description><content:encoded><![CDATA[主攻实体瘤细胞疗法！这家“年轻却资深”的公司IPO拟募资1.5亿美元，重点产品靶向ROR-1]]></content:encoded><pubDate>Sat, 29 May 2021 20:58:47 +0800</pubDate></item></channel></rss>